Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biologyVANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biot ...

About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...

Designed by Clintech Ltd. in Bulgaria, the Clintech Pico Board appears to be the first development board based on the ...

ADC Therapeutics (NYSE:ADCT) is one of the best growth stocks to buy right now. On March 10, ADC Therapeutics reported its ...

Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class ...

New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential ...

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space. Oncology or ...

Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY(R) ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today released a new CEO Corner segment ...

Merck & Co., Inc. (NYSE:MRK) has been on a strong recovery run, gaining 23% over the past year and 8% year-to-date, though the stock has pulled back some, now well below its 52-week high of $125.14.